Positive effects of correction of anemia in malignant diseases

Anemia of Chronic Disease

Volumn , Issue , 2005, Pages 489-558

  Pohl, Gudrun ^a   Ludwig, Heinz ^a  

^a WILHELMINEN HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84858207299     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (182)

1. Koeller JM. Clinical guidelines for the treatment of cancerrelated anemia. Pharmacotherapy 1998; 18:156-169.
2. Means RT Jr. Advances in the anemia of chronic disease. Int J Hematol 1999; 70:7-12.
3. Ludwig H. Epoetin in cancer-related anaemia. Nephrol Dial Transplant 1999; 14(suppl 2):85-92.
4. Erslev AJ. Erythropoietin and anemia of cancer. Eur J Haematol 2000; 64:353-358.
5. Ludwig H, Fritz E. Anemia of cancer patients: patient selection and patient stratification for epoetin treatment. Semin Oncol 1998; 25:35-38.
6. Smith RE Jr, Tchekmedyian S. Practitioners’ practical model for managing cancer-related anemia. Oncology (Huntington) 1992.
7. Reed WR, Hussey DH, DeGowin RL. Implications of the anemia of chronic disorders in patients anticipating radiotherapy. Am J Med Sci 1994; 308:9-15.
8. Sproule BJ, Mitchell HJ, Miller WF. Cardiopulmonary physiological responses to heavy exercise in patients with anemia. J Clin Invest 1960; 33:378-388.
9. Duke M, Abelmann WH. The hemodynamic response to chronic anemia. Circulation 1969; 39:503-515.
10. Brannon ES. The cardiac output in patients with chronic anemia as measured by the technique of right atrial catheterization. J Clin Invest 1945; 332.
11. Sharpey-Schafer EP. Cardiac output in severe anemia. Clin Sci 1944; 11:400.
12. Bartels EC. Anemia as the cause of severe congestive heart failure. Ann Intern Med 1937; 11:400.
13. Pickering GW, Wayne EJ. Observations on angina pectoris and intermittent claudication in anemia. Clin Sci 1933; 1:305.
14. Sanghvi LM. Electrocardiogram in chronic severe anemia. Am Heart J 1958; 56:79.
15. Wintrobe MM, Lukens JN, Lee RG. The approach to the patient with anemia. In: Lee GR, Bithell TC, Forester J, et al., eds. Wintrobe’s Clinical Hematology. 9th ed. Malvern, PA: Lea and Felbiger, 1993:715-744.
16. Varat MA, Adolph RJ, Fowler NO. Cardiovascular effects of anemia. Am Heart J 1972; 83:415-426.
17. Anderson NP. Syndrome of spoon nails, anemia, cheilitis and dysphagia. Arch Dermatol Syph 1938; 37:816.
18. Bradley SE BG. Renal function during chronic anemia in man. Blood 1947; 2:192-202.
19. Koury ST, Koury MJ, Bondurant MC, Caro J, Graber SE. Quantitation of erythropoietin-producing cells in kidneys of mice by in situ hybridization: correlation with hematocrit, renal erythropoietin mRNA, and serum erythropoietin concentration. Blood 1989; 74:645-651.
20. Spivak JL. The mechanisms of action of erythropoietin. Int J Cell Cloning 1986; 4:139-166.
21. Means RT Jr, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992; 80:1639-1647.
22. Gafter U, Kalechman Y, Orlin JB, Levi J, Sredni B. Anemia of uremia is associated with reduced in vitro cytokine secretion:immunopotentiating activity of red blood cells. Kidney Int 1994; 45:224-231.
23. Pickett JL, Theberge DC, Brown WS, Schweitzer SU, Nissenson AR. Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis 1999; 33:1122-1130.
24. Nissenson AR, Goodnough LT, Dubois RW. Anemia: not just an innocent bystander? Arch Intern Med 2003; 163:1400-1404.
25. Aisen ML, Bacon BR, Goodman AM, Chester EM. Retinal abnormalities associated with anemia. Arch Ophthalmol 1983; 101:1049-1052.
26. Ludwig H, Fritz E. Anemia in cancer patients. Semin Oncol 1998; 25:2-6.
27. Ludwig H, Birgegard G, Olmi P, et al. European Cancer Anemia Survey (ECAS): Prospective evaluation of anemia in over 15,000 cancer patients (abstr). Ann Oncol 2003; 13(suppl):623.
28. Manegold C. The causes and prognostic significance of low hemoglobin levels in tumor patients. Strahlenther Onkol 1998; 174(suppl 4):17-19.
29. Bokkel Huinink WW, de Swart CA, van Toorn DW, Morack G, Breed WP, Hillen HF, van der Hoeven JJ, Reed NS, Fairlamb DJ, Chan SY, Godfrey KA, Kristensen GB, van Tinteren H, Ehmer B. Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol 1998; 15:174-182.
30. Fein DA, Lee WR, Hanlon AL, Ridge JA, Langer CJ, Curran WJ Jr, Coia LR. Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol 1995; 13:2077-2083.
31. Mercadante S, Gebbia V, Marrazzo A, Filosto S. Anaemia in cancer: pathophysiology and treatment. Cancer Treat Rev 2000; 26:303-311.
32. Glaspy J, Cavill I. Role of iron in optimizing responses of anemic cancer patients to erythropoietin. Oncology (Huntingt) 1999; 13:461-473.
33. Gordon MS. Managing anemia in the cancer patient: old problems, future solutions. Oncologist 2002; 7:331-341.
34. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, Djulbegovic B, Goode MJ, Jakubowski AA, Lee SJ, Miller CB, Rarick MU, Regan DH, Browman GP, Gordon MS. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002; 20:4083-4107.
35. Ludwig H, Rai K, Blade J, Dammacco F, Degos L, Itri L, Kyle R, Liso V, Littlewood TJ, Mandelli F, Meloni G, Molica S, Osterborg A, Pangalis GA, San Miguel J, Schmitt B, Voliotis D. Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia:epoetin treatment recommendations. Hematol J 2002; 3:121-130.
36. Sabbatini P. The relationship between anemia and quality of life in cancer patients. Oncologist 2000; 5(suppl 2):19-23.
37. Jacobs K, Shoemaker C, Rudersdorf R, Neill SD, Kaufman RJ, Mufson A, Seehra J, Jones SS, Hewick R, Fritsch EF. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 1985; 313:806-810.
38. Lin FK, Suggs S, Lin CH, Browne JK, Smalling R, Egrie JC, Chen KK, Fox GM, Martin F, Stabinsky Z. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 1985; 82:7580-7584.
39. Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. Hematology (Am Soc Hematol Educ Program) 2001; 47-61.
40. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassemia. Lancet 2002; 360:516-520.
41. Barrett-Lee PJ, Bailey NP, O’Brien ME, Wager E. Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer 2000; 82:93-97.
42. Coiffier B, Guastalla JP, Pujade-Lauraine E, Bastit P. Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy: results of a retrospective survey. Eur J Cancer 2001; 37:1617-1623.
43. Ortega A, Dranitsaris G, Puodziunas A. A clinical and economic evaluation of red blood cell transfusions in patients receiving cancer chemotherapy. Int J Technol Assess Health Care 1998; 14:788-798.
44. Faulds D, Sorkin EM. Epoetin (recombinant human ery thropoietin). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis. Drugs 1989; 38:863-899.
45. Lacombe C, Da Silva JL, Bruneval P, Fournier JG, Wendling F, Casadevall N, Camilleri JP, Bariety J, Varet B, Tambourin P. Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. J Clin Invest 1988; 81:620-623.
46. Lin FK, Suggs S, Lin CH, Browne JK, Smalling R, Egrie JC, Chen KK, Fox GM, Martin F, Stabinsky Z. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 1985; 82:7580-7584.
47. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316:73-78.
48. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986; 2:1175-1178.
49. Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990; 322:1689-1692.
50. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S, Procrit Study Group. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997; 15:1218-1234.
51. Cascinu S, Fedeli A, Del Ferro E, Luzi FS, Catalano G. Recombinant human erythropoietin treatment in cisplatinassociated anemia: a randomized, double-blind trial with placebo. J Clin Oncol 1994; 12:1058-1062.
52. Demetri GD, Kris M, Wade J, Degos L, Cella D, Procrit Study Group. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998; 16:3412-3425.
53. Abels R. Erythropoietin for anaemia in cancer patients. Eur J Cancer 1993; 29A(suppl 2):2-8.
54. Henry DH. Recombinant human erythropoietin treatment of anemic cancer patients. Cancer Pract 1996; 4:180-184.
55. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001; 84(suppl 1):3-10.
56. Reigner B, Jordan A, Panier J, Glaspy F. CERA (continuous erythropoiesis receptor activator), a novel erythropoietic agent: Dose-dependent response in phase I studies [abstr]. Proc Am Soc Clin Oncol 2003; 22:732.
57. Haselbeck A, Reigner B, Jordan P, Pannier A, Glaspy J. Preclinical and phase I pharmacokinetic and mode-of-action studies of CERA (continuous erythropoiesis receptor activator), a novel erythropoietic agent with an extended serum half-life [abstr]. Proc Am Soc Clin Oncol 2003; 22:732.
58. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, Djulbegovic B, Goode MJ, Jakubowski AA, Lee SJ, Miller CB, Rarick MU, Regan DH, Browman GP, Gordon MS. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002; 100:2303-2320.
59. Beguin Y. Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients. Haematologica 2002; 87:1209-1221.
60. Ludwig H, Pecherstorfer M, Leitgeb C, Fritz E. Recombinant human erythropoietin for the treatment of chronic anemia in multiple myeloma and squamous cell carcinoma. Stem Cells 1993; 11:348-355.
61. Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller-Ziegler L, Essers U, Greil R, Grossi A, Jager G. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin’s lymphoma: dose finding and identification of predictors of response. Blood 1995; 86:4446-4453.
62. Auerbach M, Barker L, Bahrain H, Trout R, Mcllwain M, Ballard H. Intravenous iron (IV Fe) optimises the response to erythropoietin (Epo) in patients with anaemia of cancer and cancer chemotherapy: results of a multicenter, openlabel, randomized trial [abstr]. Blood 2001; 98(suppl).
63. Ludwig H, Fritz E, Leitgeb C, Pecherstorfer M, Samonigg H, Schuster J. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 1994; 84:1056-1063.
64. Adamson JW, Ludwig H. Predicting the hematopoietic response to recombinant human erythropoietin (epoetin alfa) in the treatment of the anemia of cancer. Oncology 1999; 56:46-53.
65. Iki S, Yagisawa M, Ohbayashi Y, Sato H, Urabe A. Adverse effect of erythropoietin in myeloproliferative disorders. Lancet 1991; 337:187-188.
66. Ehmer B, Roshan Y, Mocks J, Franke W. A meta-analysis on the safety of epoitin-B therapy in cancer patients. In: Smyth JF, Boogaerts MA, Ehmer BR, eds. rhuErythropoietin in Cancer Supportive Treatment. New York: Marcel Dekker, 1996:13-34.
67. Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K, Verma A. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001; 61:3561-3565.
68. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346:469-475.
69. Barosi G, Marchetti M, Liberato NL. Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. Br J Cancer 1998; 78:781-787.
70. Demetri GD, Gabrilove JL, Blasi MV, Hill RJ Jr, Glaspy J. Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy. Clin Breast Cancer 2002; 3:45-51.
71. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, doubleblind, placebo-controlled trial. J Clin Oncol 2001; 19:2865-2874.
72. Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, Slavin MB, Glaspy JA. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002; 95:888-895.
73. Ludwig H, Fritz E, Kotzmann H, Hocker P, Gisslinger H, Barnas U. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990; 322:1693-1699.
74. Oster W, Herrmann F, Gamm H, Zeile G, Lindemann A, Muller G, Brune T, Kraemer HP, Mertelsmann R. Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. J Clin Oncol 1990; 8:956-962.
75. Platanias LC, Miller CB, Mick R, Hart RD, Ozer H, McEvilly JM, Jones RJ, Ratain MJ. Treatment of chemotherapyinduced anemia with recombinant human erythropoietin in cancer patients. J Clin Oncol 1991; 9:2021-2026.
76. Henry DH. Clinical application of recombinant erythropoietin in anemic cancer patients. Hematol Oncol Clin North Am 1994; 8:961-973.
77. Barlogie B. Treatment of the anemia of multiple myeloma:the role of recombinant human erythropoietin. Semin Hematol 1993; 30:25-27.
78. Mittelman M, Zeidman A, Fradin Z, Magazanik A, Lewinski UH, Cohen A. Recombinant human erythropoietin in the treatment of multiple myeloma-associated anemia. Acta Haematol 1997; 98:204-210.
79. Musto P, Falcone A, D’Arena G, Scalzulli PR, Matera R, Minervini MM, Lombardi GF, Modoni S, Longo A, Carotenuto M. Clinical results of recombinant erythropoietin in transfusion-dependent patients with refractory multiple myeloma: role of cytokines and monitoring of erythropoiesis. Eur J Haematol 1997; 58:314-319.
80. Silvestris F, Romito A, Fanelli P, Vacca A, Dammacco F. Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma. Ann Hematol 1995; 70:313-318.
81. Dammacco F, Silvestris F, Castoldi GL, Grassi B, Bernasconi C, Nadali G, Perona G, De Laurenzi A, Torelli U, Ascari E, Rossi Ferrini PL, Caligaris-Cappio F, Pileri A, Resegotti L. The effectiveness and tolerability of epoetin alfa in patientswith multiple myeloma refractory to chemotherapy. Int J Clin Lab Res 1998; 28:127-134.
82. Dammacco F, Castoldi G, Rodjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 2001; 113:172-179.
83. Osterborg A, Boogaerts MA, Cimino R, Essers U, Holowiecki J, Juliusson G, Jager G, Najman A, Peest D. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin’s Lymphoma. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin’s lymphoma- a randomized multicenter study. Blood 1996; 87:2675-2682.
84. Osterborg A, Brandberg Y, Molostova V, Iosava G, Abdulkadyrov K, Hedenus M, Messinger D. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002; 20:2486-2494.
85. Mittelman M, Neumann D, Peled A, Kanter P, Haran-Ghera N. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci USA 2001; 98:5181-5186.
86. Hedenus M, Hansen S, Taylor K, Arthur C, Emmerich B, Dewey C, Watson D, Rossi G, Osterborg A. Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol 2002; 119:79-86.
87. Cazzola M, Beguin Y, Kloczko J, Spicka I, Coiffier B. Onceweekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 2003; 122:386-393.
88. Hedenus M, Adriansson M, Miguel JS, Kramer MH, Schipperus MR, Juvonen E, Taylor K, Belch A, Altes A, Martinelli G, Watson D, Matcham J, Rossi G, Littlewood TJ. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, doubleblind, placebo-controlled study. Br J Haematol 2003; 122:394-403.
89. Rose E, Rai K, Revicki D, Brown R, Reblando J. Clinical and health status assessments in anemic chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa (EPO) [abstr]. Blood 1994; 84(suppl 1):526.
90. Siakantaris MP, Angelopoulou MK, Vassilakopoulos TP, Dimopoulou MN, Kontopidou FN, Pangalis GA. Correction of disease related anaemia of B-chronic lymphoproliferative disorders by recombinant human erythropoietin: maintenance is necessary to sustain response. Leuk Lymphoma 2000; 40:141-147.
91. Pangalis GA, Siakantaris MP, Angelopoulou MK, Vassilakopoulos TP, Dimopoulou MN, Kyrtsonis MC, Konstantopoulos K, Tsaftaridis P, Vaiopoulos GA, Kontopidou FN. Downstaging Rai stage III B-chronic lymphocytic leukemia patients with the administration of recombinant human erythropoietin. Haematologica 2002; 87:500-506.
92. Stein RS. The role of erythropoietin in the anemia of myelodysplastic syndrome. Clin Lymphoma. In press.
93. Cazzola M, Ponchio L, Pedrotti C, Farina G, Cerani P, Lucotti C, Novella A, Rovati A, Bergamaschi G, Beguin Y. Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy. Haematologica 1996; 81:434-441.
94. Matsuda A, Kishimoto K, Yoshida K, Yagasaki F, Ito Y, Sakata T, Kawai N, Ino H, Hirashima K, Bessho M. Longterm follow-up of patients with aplastic anemia and refractory anemia responding to combination therapy with recombinant human granulocyte colony-stimulating factor and erythropoietin. Int J Hematol 2002; 76:244-250.
95. Stebler C, Tichelli A, Dazzi H, Gratwohl A, Nissen C, Speck B. High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: a pilot study. Exp Hematol 1990; 18:1204-1208.
96. Hellstrom E, Birgegard G, Lockner D, Helmers C, Ost A, Wide L. Treatment of myelodysplastic syndromes with recombinant human erythropoietin. Eur J Haematol 1991; 47:355-360.
97. Casadevall N, Belanger C, Goy A, Varet B, Lang J, Poisson D. High-dose recombinant human erythropoietin administered intravenously for the treatment of anaemia in myelodysplastic syndromes. Acta Haematol 1992; 87(suppl 1):25-27.
98. Ludwig H, Fritz E, Leitgeb C, Krainer M, Kuhrer I, Sagaster P, Umek H. Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. Ann Oncol 1993; 4:161-167.
99. Stone RM, Bernstein SH, Demetri G, Facklam DP, Arthur K, Andersen J, Aster JC, Kufe D. Therapy with recombinant human erythropoietin in patients with myelodysplastic syndromes. Leuk Res 1994; 18:769-776.
100. Rose EH, Abels RI, Nelson RA, McCullough DM, Lessin L. The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS). Br J Haematol 1995; 89:831-837.
101. Bernell P, Stenke L, Wallvik J, Hippe E, Hast R. A sequential erythropoietin and GM-CSF schedule offers clinical benefits in the treatment of anaemia in myelodysplastic syndromes. Leuk Res 1996; 20:693-699.
102. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995; 89:67-71.
103. Hellstrom-Lindberg E, Birgegard G, Carlsson M, Carneskog J, Dahl IM, Dybedal I, Grimfors G, Merk K, Tangen JM, Winqvist I. A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes. Leuk Lymphoma 1993; 11:221-228.
104. Imamura M, Kobayashi M, Kobayashi S, Yoshida K, Mikuni C, Ishikawa Y, Matsumoto S, Sakamaki S, Niitsu Y, Hinoda Y. Failure of combination therapy with recombinant granulocyte colony-stimulating factor and erythropoietin in myelodysplastic syndromes. Ann Hematol 1994; 68:163-166.
105. Negrin RS, Stein R, Doherty K, Cornwell J, Vardiman J, Krantz S, Greenberg PL. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin:evidence for in vivo synergy. Blood 1996; 87:4076-4081.
106. Remacha AF, Arrizabalaga B, Villegas A, Manteiga R, Calvo T, Julia A, Fernandez F, I, Gonzalez FA, Font L, Junca J, del Arco A, Malcorra JJ, Equiza EP, de Mendiguren BP, Romero M. The Spanish Erythropathology Group. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. Haematologica 1999; 84:1058-1064.
107. Mantovani L, Lentini G, Hentschel B, Wickramanayake PD, Loeffler M, Diehl V, Tesch H. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin. Br J Haematol 2000; 109:367-375.
108. Runde V, Aul C, Ebert A, Grabenhorst U, Schneider W. Sequential administration of recombinant human granulocyte-macrophage colony-stimulating factor and human erythropoietin for treatment of myelodysplastic syndromes. Eur J Haematol 1995; 54:39-45.
109. Stasi R, Pagano A, Terzoli E, Amadori S. Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes. Br J Haematol 1999; 105:141-148.
110. Economopoulos T, Mellou S, Papageorgiou E, Pappa V, Kokkinou V, Stathopoulou E, Pappa M, Raptis S. Treatment of anemia in low risk myelodysplastic syndromes with granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin. Leukemia 1999; 13:1009-1012.
111. Miller AM, Noyes WE, Taetle R, List AF. Limited erythropoietic response to combined treatment with recombinant human interleukin 3 and erythropoietin in myelodysplastic syndrome. Leuk Res 1999; 23:77-83.
112. Besa EC, Kunselman S, Nowell PC, The Central Pennsylvania Oncology Group. A pilot trial of 13-cis-retinoic acid and alpha-tocopherol with recombinant human erythropoietin in myelodysplastic syndrome patients with progressive or transfusion- dependent anemias. Leuk Res 1998; 22:741-749.
113. Thompson JA, Gilliland DG, Prchal JT, Bennett JM, Larholt K, Nelson RA, Rose EH, Dugan MH, GM=EPO MDS Study Group. Effect of recombinant human erythropoietin combined with granulocyte=macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. Blood 2000; 95:1175-1179.
114. Terpos E, Mougiou A, Kouraklis A, Chatzivassili A, Michalis E, Giannakoulas N, Manioudaki E, Lazaridou A, Bakaloudi V, Protopappa M, Liapi D, Grouzi E, Parharidou A, Symeonidis A, Kokkini G, Laoutaris NP, Vaipoulos G, Anagnostopoulos NI, Christakis JI, Meletis J, Bourantas KL, Zoumbos NC, Yataganas X, Viniou NA. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. Br J Haematol 2002; 118:174-180.
115. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I, Grimfors G, Hesse-Sundin E, Hjorth M, Kanter-Lewensohn L, Linder O, Luthman M, Lofvenberg E, Oberg G, Porwit-MacDonald A, Radlund A, Samuelsson J, Tangen JM, Winquist I, Wisloff F. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin þ granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003; 120:1037-1046.
116. Vinh TT, Lewis BH, Yao B, Yim J. Initial experience with darbepoetin alfa in patients with myelodysplastic syndrome (MDS) [abstr]. Proc Am Soc Clin Oncol 2003; 22:613.
117. Ludwig H, Sundal E, Pecherstorfer M, Leitgeb C, Bauernhofer T, Beinhauer A, Samonigg H, Kappeler AW, Fritz E. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer 1995; 76:2319-2329.
118. Miller CB, Platanias LC, Mills SR, Zahurak ML, Ratain MJ, Ettinger DS, Jones RJ. Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anemia. J Natl Cancer Inst 1992; 84:98-103.
119. Cascinu S, Fedeli A, Fedeli SL, Catalano G. Cisplatinassociated anaemia treated with subcutaneous erythropoietin. A pilot study. Br J Cancer 1993; 67:156-158.
120. Case DC Jr, Bukowski RM, Carey RW, Fishkin EH, Henry DH, Jacobson RJ, Jones SE, Keller AM, Kugler JW, Nichols CR. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 1993; 85:801-806.
121. Tsukuda M, Mochimatsu I, Nagahara T, Kokatsu T, Sawaki S, Kubota A, Furkawa M, Arai Y. Clinical application of recombinant human erythropoietin for treatments in patients with head and neck cancer. Cancer Immunol Immunother 1993; 36:52-56.
122. Kasper C, Terhaar A, Fossa A, Welt A, Seeber S, Nowrousian MR. Recombinant human erythropoietin in the treatment of cancer-related anaemia. Eur J Haematol 1997; 58:251-256.
123. Pawlicki M, Jassem J, Bosze P, Lotan C, Kurteva GP, Siddiqui M, Kosmidis PA, Rigatos GA, Kansu E, Durkovic P, Aziz Z, Al Idrissi H, Roth A, Cozma G. A multicenter study of recombinant human erythropoietin (epoetin alpha) in the management of anemia in cancer patients receiving chemotherapy. Anticancer Drugs 1997; 8:949-957.
124. Oberhoff C, Neri B, Amadori D, Petry KU, Gamucci T, Rebmann U, Nowrousian MR, Voigtmann R, Monfardini S, Armand JP, Herrmann R, Netter-Pinon J, Tubiana-Mathieu N, Zwierzina H. Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann Oncol 1998; 9:255-260.
125. Porter JC, Leahey A, Polise K, Bunin G, Manno CS. Recombinant human erythropoietin reduces the need for erythrocyte and platelet transfusions in pediatric patients with sarcoma: a randomized, double-blind, placebo-controlled trial. J Pediatr 1996; 129:656-660.
126. Wurnig C, Windhager R, Schwameis E, Kotz R, Zoubek A, Stockenhuber F, Kurz RW. Prevention of chemotherapyinduced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a double-blind, randomized, phase III study). Transfusion 1996; 36:155-159.
127. Kurz C, Marth C, Windbichler G, Lahousen M, Medl M, Vavra N, Sevelda P. Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study. Gynecol Oncol 1997; 65:461-466.
128. Tsukuda M, Yuyama S, Kohno H, Itoh K, Kokatsu T, Kawai S. Effectiveness of weekly subcutaneous recombinant human erythropoietin administration for chemotherapy-induced anemia. Biotherapy 1998; 11:21-25.
129. Quirt I, Micucci S, Moran LA, Pater J, Browman G, Systemic Treatment Program Committee. Erythropoietin in the management of patients with nonhematologic cancer receiving chemotherapy. Cancer Prev Control 1997; 1:241-248.
130. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, doubleblind, placebo-controlled trial. J Clin Oncol 2001; 19:2865-2874.
131. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-timesweekly dosing. J Clin Oncol 2001; 19:2875-2882.
132. Rushing DA, Einhorn LH, Wildgust M. Epoetin alfa 40,000 U once weekly significantly improves hemoglobin and quality of life in anemic colorectal cancer patients [abstr]. Proc Am Soc Clin Oncol 2003; 22:771.
133. Campos SM. Epoetin alfa 40,000 U once weekly significantly improves hemoglobin and quality of life in anemic patients with ovarian cancer [abstr]. Proc Am Soc Clin Oncol 2003; 22:774.
134. Quirt I, Robeson C, Lau CY, Kovacs M, Burdette-Radoux S, Dolan S, Tang SC, McKenzie M, Couture F. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 2001; 19:4126-4134.
135. Markman M, Reichman B, Hakes T, Rubin S, Jones W, Lewis JL Jr, Barakat R, Curtin J, Almadrones L, Hoskins W. The use of recombinant human erythropoietin to prevent carboplatin-induced anemia. Gynecol Oncol 1993; 49:172-176.
136. Del Mastro L, Venturini M, Lionetto R, Garrone O, Melioli G, Pasquetti W, Sertoli MR, Bertelli G, Canavese G, Costantini M, Rosso R. Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 1997; 15:2715-2721.
137. Thatcher N, De Campos ES, Bell DR, Steward WP, Varghese G, Morant R, Vansteenkiste JF, Rosso R, Ewers SB, Sundal E, Schatzmann E, Stocker H. Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer 1999; 80:396-402.
138. Dunphy FR, Harrison BR, Dunleavy TL, Rodriguez JJ, Hilton JG, Boyd JH. Erythropoietin reduces anemia and transfusions:a randomized trial with or without erythropoietin during chemotherapy. Cancer 1999; 86:1362-1367.
139. Kunikane H, Watanabe K, Fukuoka M, Saijo N, Furuse K, Ikegami H, Ariyoshi Y, Kishimoto S. Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer. Int J Clin Oncol 2001; 6:296-301.
140. Bamias A, Aravantinos G, Kalofonos C, Timotheadou N, Siafaka V, Vlahou I, Janinis D, Pectasides D, Pavlidis N, Fountzilas G. Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group. Oncology 2003; 64:102-110.
141. O’Shaughnessy J. Effects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy. Clin Breast Cancer 2002; (suppl 3):116-120.
142. Hudis C, Williams D, Gralow JR, PROCRIT Study Group. Epoetin alfa maintains hemoglobin and quality of life in breast cancer patients receiving conventional adjuvant chemotherapy:final report [abstr]. Proc Am Soc Clin Oncol 2003; 22:767.
143. Crawford J, Robert F, Perry M, Belani P, Sarokhan B. Epoetin alfa 40,000 U once weekly maintains hemoglobin in advanced non-small-cell lung cancer patients receiving first-line chemotherapy [abstr]. Proc Am Soc Clin Oncol 2003; 22:13.
144. McCormack M, Nias AH, Smith E. Chronic anaemia, hyperbaric oxygen and tumour radiosensitivity. Br J Radiol 1990; 63:752-759.
145. Grant DG, Hussain A, Hurman D. Pre-treatment anaemia alters outcome in early squamous cell carcinoma of the larynx treated by radical radiotherapy. J Laryngol Otol 1999; 113:829-833.
146. Grogan M, Thomas GM, Melamed I, Wong FL, Pearcey RG, Joseph PK, Portelance L, Crook J, Jones KD. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 1999; 86:1528-1536.
147. Frommhold H, Guttenberger R, Henke M. The impact of blood hemoglobin content on the outcome of radiotherapy. The Freiburg experience. Strahlenther Onkol 1998; 174(suppl 4):31-34.
148. Dusenbery KE, McGuire WA, Holt PJ, Carson LF, Fowler JM, Twiggs LB, Potish RA. Erythropoietin increases hemoglobin during radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys 1994; 29:1079-1084.
149. Lavey RS, Dempsey WH. Erythropoietin increases hemoglobin in cancer patients during radiation therapy. Int J Radiat Oncol Biol Phys 1993; 27:1147-1152.
150. Sweeney PJ, Nicolae D, Ignacio L, Chen L, Roach M, III, Wara W, Marcus KC, Vijayakumar S. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open-labelled, phase II trial. Br J Cancer 1998; 77:1996-2002.
151. Glaser CM, Millesi W, Kornek GV, Lang S, Schull B, Watzinger F, Selzer E, Lavey RS. Impact of hemoglobin level anduse of recombinant erythropoietinonefficacy ofpreoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001; 50:705-715.
152. Blohmer JU, Wurschmidt F, Petry U, Weise G, Sehouli J, Kimmig R. Sixth interim analysis of a prospective, randomized, open and controlled AGO- and NOGGOintergroup study: sequential adjuvant chemo-radiotherapy with vs without epoetin alfa for pts with high-risk cervical cancer [abstr]. Proc Am Soc Clin Oncol 2003; 22.
153. Tsuji Y, Kambayashi J, Shiba E, Sakon M, Kawasaki T, Mori T. Effect of recombinant human erythropoietin on anaemia after gastrectomy: a pilot study. Eur J Surg 1995; 161:29-33.
154. Braga M, Gianotti L, Gentilini O, Vignali A, Di C. Erythropoietic response induced by recombinant human erythropoietin in anemic cancer patients candidate to major abdominal surgery. Hepatogastroenterology 1997; 44:685-690.
155. Kettelhack C, Hones C, Messinger D, Schlag PM. Randomized multicentre trial of the influence of recombinant human erythropoietin on intraoperative and postoperative transfusion need in anaemic patients undergoing right hemicolectomy for carcinoma. Br J Surg 1998; 85:63-67.
156. Rau B, Schlag PM, Willeke F, Herfarth C, Stephan P, Franke W. Increased autologous blood donation in rectal cancer by recombinant human erythropoietin (rhEPO). Eur J Cancer 1998; 34:992-998.
157. Scott SN, Boeve TJ, McCulloch TM, Fitzpatrick KA, Karnell LH. The effects of epoetin alfa on transfusion requirements in head and neck cancer patients: a prospective, randomized, placebo-controlled study. Laryngoscope 2002; 112:1221-1229.
158. Kosmadakis N, Messaris E, Maris A, Katsaragakis S, Leandros E, Konstadoulakis MM, Androulakis G. Perioperative erythropoietin administration in patients with gastrointestinal tract cancer: prospective randomized double-blind study. Ann Surg 2003; 237:417-421.
159. Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990; 322:1689-1692.
160. Klaesson S, Ringden O, Ljungman P, Lonnqvist B, Wennberg L. Reduced blood transfusions requirements after allogeneic bone marrow transplantation: results of a randomised, double-blind study with high-dose erythropoietin. Bone Marrow Transplant 1994; 13:397-402.
161. Link H, Boogaerts MA, Fauser AA, Slavin S, Reiffers J, Gorin NC, Carella AM, Mandelli F, Burdach S, Ferrant A. A controlled trial of recombinant human erythropoietin after bone marrow transplantation. Blood 1994; 84:3327-3335.
162. Pene R, Appelbaum FR, Fisher L, Lilleby K, Nemunaitis J, Storb R, Buckner CD. Use of granulocyte-macrophage colony-stimulating factor and erythropoietin in combination after autologous marrow transplantation. Bone Marrow Transplant 1993; 11:219-222.
163. Chao NJ, Schriber JR, Long GD, Negrin RS, Catolico M, Brown BW, Miller LL, Blume KG. A randomized study of erythropoietin and granulocyte colony-stimulating factor (GCSF) versus placebo and G-CSF for patients with Hodgkin’s and non-Hodgkin’s lymphoma undergoing autologous bone marrow transplantation. Blood 1994; 83:2823-2828.
164. Daneryd P. Epoetin alfa for protection of metabolic and exercise capacity in cancer patients. Semin Oncol 2002; 29:69-74.
165. Bottomley A, Thomas R, Van Steen K, Flechtner H, Djulbegovic B. Human recombinant erythropoietin and quality of life:a wonder drug or something to wonder about? Lancet Oncol 2002; 3:145-153.
166. Van Belle SJ, Cocquyt V. Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. Crit Rev Oncol Hematol 2003; 47:1-11.
167. Becker A, Stadler P, Lavey RS, Hansgen G, Kuhnt T, Lautenschlager C, Feldmann HJ, Molls M, Dunst J. Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2000; 46:459-466.
168. Dunst J, Pigorsch S, Hansgen G, Hintner I, Lautenschlager C, Becker A. Low hemoglobin is associated with increased serum levels of vascular endothelial growth factor (VEGF) in cancer patients. Does anemia stimulate angiogenesis? Strahlenther Onkol 1999; 175:93-96.
169. Semenza GL, Agani F, Feldser D, Iyer N, Kotch L, Laughner E, Yu A. Hypoxia, HIF-1, and the pathophysiology of common human diseases. Adv Exp Med Biol 2000; 475:123-130.
170. Liang BC. Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines. J Neurooncol 1996; 29:149-155.
171. Takigawa N, Segawa Y, Okahara M, Maeda Y, Takata I, Kataoka M, Fujii M. Prognostic factors for patients with advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation. Lung Cancer 1996; 15:67-77.
172. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer:a systemic, quantitative review. Cancer 2001; 91:2214-2221.
173. Girinski T, Pejovic-Lenfant MH, Bourhis J, Campana F, Cosset JM, Petit C, Malaise EP, Haie C, Gerbaulet A, Chassagne D. Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: results of a retrospective study of 386 patients. Int J Radiat Oncol Biol Phys 1989; 16:37-42.
174. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, doubleblind, placebo-controlled trial. J Clin Oncol 2001; 19:2865-2874.
175. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003; 4:459-460.
176. Mughal T. Anemia in patients with cancer: an overview. In:Bokemeyer C, Ludwig H, eds. Anemia in Cancer. Elsevier, 2001:15-23.
177. Bokemeyer C. Causes of anaemia in cancer patients with emphasis on treatment factors. In: Bokemeyer C, Ludwig H, eds. Anemia in Cancer. : Elsevier, 2001:43-54.
178. Case DC Jr, Bukowski RM, Carey RW, Fishkin EH, Henry DH, Jacobson RJ, Jones SE, Keller AM, Kugler JW, Nichols CR. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 1993; 85:801-806.
179. de Campos E, Radford J, Steward W, Milroy R, Dougal M, Swindell R, Testa N, Thatcher N. Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer. J Clin Oncol 1995; 13:1623-1631.
180. Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, Siena S, Gateley J, Tomita D, Colowick AB, Musil J. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002; 94:1211-1220.
181. Olsson AM, Svensson JH, Sundstrom J, Bergstrom S, Edekling T, Carlsson G, Hansen J, Svensson B, Albertsson M. Erythropoietin treatment in metastatic breast cancer-effects on Hb, quality of life and need for transfusion. Acta Oncol 2002; 41:517-524.
182. Glaspy J, Degos L, Dicato M, Demetri GD. Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum- and nonplatinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials. Oncologist 2002; 7:126-135.